At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
Rintatolimod +1 moredrug
Likely dose
Rintatolimod 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ampligen® in Patients With Post-COVID Conditions
In Brief
A Phase 2 clinical trial evaluating Rintatolimod and Placebo / Normal Saline for Post COVID-19 Condition and Long COVID. Completed, enrolled 80 participants across 5 sites.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of Ampligen® administered twice weekly by intravenous (IV) infusions in subjects experiencing the Post-COVID Condition of fatigue.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost COVID-19 Condition, Long COVID
CountriesUnited States
CollaboratorsAmarex Clinical Research
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedOct 2022
Enrollment StartJun 2023
Primary CompletionNov 2023
Study CompletionNov 2023
TodayJul 2026
First PostedOct 24, 2022
Enrollment StartJun 30, 2023
Primary CompletionNov 17, 2023
Study CompletionNov 30, 2023
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 3.7 years ago
Interventions
Rintatolimoddrug
100 to 400 mg twice weekly
Placebo / Normal Salineother
40 to 160 mL twice weekly